Heroin-Assisted Treatment: Diacetylmorphine Prescribing Evidence and Outcomes

What Heroin-Assisted Treatment Involves

Heroin-assisted treatment (HAT) involves the prescription of pharmaceutical-grade diacetylmorphine (heroin) to individuals with severe, chronic opioid use disorder who have not responded to standard medication-assisted treatments including methadone maintenance and buprenorphine therapy. Participants attend clinical facilities two to three times daily where they self-administer prescribed doses of injectable or inhalable diacetylmorphine under medical supervision. The pharmaceutical product is manufactured to pharmaceutical standards, ensuring known purity and dosage, eliminating the contamination and dosing uncertainty of illicit heroin that drives overdose.

HAT is explicitly positioned as a third-line treatment. Individuals must have documented histories of treatment failure with both methadone and buprenorphine before HAT eligibility. This ensures that HAT serves only the most treatment-resistant population—estimated at 10-15% of individuals with severe opioid use disorder—for whom conventional evidence-based treatments have proven insufficient. The clinical framework includes comprehensive psychosocial support, medical monitoring, and ongoing assessment of treatment response.

The rationale for HAT parallels the logic of all medication-assisted treatment: providing a pharmaceutical-grade opioid agonist under medical supervision is vastly preferable to continued use of contaminated illicit opioids in uncontrolled settings. Just as methadone replaced illicit heroin for many individuals, HAT extends this principle to those for whom methadone and buprenorphine proved inadequate. The distinction is the medication used, not the fundamental treatment approach.

Clinical Trial Evidence

The evidence base for HAT is substantial, including multiple large randomized controlled trials conducted in Switzerland, Netherlands, Germany, Spain, Canada, and the United Kingdom. The landmark Swiss PROVE trial (1994) enrolled over 1,000 participants with severe treatment-resistant opioid dependence, demonstrating dramatic reductions in illicit drug use, criminal activity, unemployment, and homelessness. Subsequent randomized trials consistently confirmed these findings: HAT reduces illicit drug use 60-80% compared to methadone alone in treatment-resistant populations.

The North American Opiate Medication Initiative (NAOMI) trial, conducted in Vancouver and Montreal, randomized treatment-resistant opioid-dependent individuals to supervised injectable diacetylmorphine versus oral methadone. Results showed that HAT participants had significantly higher treatment retention (87.8% versus 54.1%), greater reductions in illicit heroin use, reduced criminal activity, and improved health and social functioning. The Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) further confirmed these findings and demonstrated that hydromorphone could serve as an alternative to diacetylmorphine with similar effectiveness.

Mortality Reduction and Safety Profile

HAT produces significant mortality reduction through multiple mechanisms: elimination of overdose risk from contaminated illicit supply; regular medical monitoring detecting and treating health conditions; nutritional and housing support improving overall health; and reduced injection-related infections through sterile technique and equipment. Studies following HAT participants over years demonstrate mortality rates approximately 50% lower than matched individuals not receiving HAT, with the mortality reduction primarily attributable to eliminated overdose deaths and reduced infectious disease.

Safety within supervised HAT facilities is well-documented: despite thousands of supervised injections administered daily across multiple countries over decades, fatal overdoses within HAT facilities are extraordinarily rare. The controlled dosing, medical supervision, and immediate access to overdose reversal equipment create conditions where fatal overdose is essentially prevented. Medical complications (respiratory depression, seizures) do occur but are managed effectively within the clinical setting. The safety record of supervised HAT compares favorably to many standard medical procedures.

Cost-Effectiveness and Healthcare Savings

Despite the higher direct treatment costs of HAT compared to oral methadone (due to supervised administration and pharmaceutical costs), economic analyses consistently demonstrate that HAT produces net healthcare savings through dramatically reduced emergency department utilization, hospitalizations, and justice system involvement. The average untreated individual with severe opioid use disorder generates approximately 40,000-80,000 dollars annually in emergency, hospital, and justice system costs. HAT typically costs 15,000-25,000 dollars per participant annually, representing substantial net savings.

Additionally, HAT participants show improved employment rates and housing stability, reducing social service costs and generating tax revenue. The economic case for HAT in treatment-resistant populations is compelling: even considering the higher per-person treatment costs, the reduction in crisis-driven healthcare and justice expenditures produces overall fiscal savings for the healthcare and public safety systems.

International Implementation and Lessons

Switzerland pioneered HAT implementation in 1994 and now operates over 20 HAT clinics serving approximately 1,500 participants. The Swiss experience demonstrates long-term program sustainability, community acceptance development, and positive population-level outcomes including reduced street-level heroin scenes and associated crime. Germany, Netherlands, Denmark, and the United Kingdom have subsequently implemented HAT programs based on the Swiss model, with similar positive outcomes documented in each national context.

Canada implemented HAT through research trials and subsequently through clinical access programs. The Vancouver experience, combining HAT with supervised consumption sites and comprehensive harm reduction infrastructure, provides a model for integrated harm reduction service delivery. The Canadian experience also demonstrates the political challenges of HAT implementation, with programs facing opposition despite strong evidence, highlighting the gap between scientific evidence and political acceptability in addiction policy.

Legal Status and Barriers in the United States

Diacetylmorphine is classified as Schedule I under the U.S. Controlled Substances Act, defined as having no accepted medical use and high abuse potential. This classification legally prevents HAT implementation in the United States regardless of clinical evidence. Changing this classification would require either Congressional action or DEA reclassification proceedings—both politically challenging given the stigma associated with heroin. Some advocates argue for hydromorphone-based HAT (using a Schedule II medication) as a legally feasible alternative, based on the SALOME trial demonstrating similar effectiveness.

The absence of HAT as a treatment option in the United States means that the 10-15% of individuals with severe opioid use disorder who do not respond to methadone or buprenorphine have no evidence-based pharmacological alternative. These individuals face continued illicit fentanyl use with its extreme overdose mortality risk. As the fentanyl crisis intensifies, the medical case for HAT availability as a third-line treatment option continues to strengthen.